Reza Madadi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Reza Madadi has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
- Ali Ramazani
Department of Pharmaceutical Biotechnology, School of Pharmacy, Zanjan University of Medical Sciences, Zanjan 4513956184, Iran
1 shared publication - Armin Bordbar
Dept. of Cardiology, School of Medicine, Zanjan University of Medical Sciences, Zanjan, Iran
1 shared publication Fereshteh Ebrahimi
Department Pharmaceutical Biotechnology, School of Pharmacy, Zanjan University of Medical Sciences, Zanjan, Iran
1 shared publicationHamid Khederlou
Department of Cardiology, Zanjan University of Medical sciences, Zanjan, Iran
1 shared publicationMahnaz Yousefi Ramandi
Department of Cardiology, Zanjan University of Medical sciences, Zanjan, Iran
1 shared publication- Masoud Hassanzadeh Makoui
Department of Immunology, School of Medicine, Zanjan University of Medical Sciences, Zanjan, Iran
1 shared publication
Latest Publications
- Open Access
- 30 June 2026
- Published by Maad Rayan Publishing Company in Journal of Cardiovascular and Thoracic Research
- Vol. 18 (2) , 116-122
Impact of Empagliflozin on mRNA Levels of Cardiotrophin-1 and GDF-15 in Patients with Type 2 Diabetes and ST-Segment Elevation Myocardial Infarction Undergoing PCI: A Double-Blind Pilot Trial
Introduction: Given the proven cardiovascular benefits of Empagliflozin (EM), we aimed to investigate the effect of Empagliflozin on Cardiotrophin-1 (CTF-1) and growth differentiation factor-15 (GDF-15) expressions in circulating monocytes in type 2 diabetic patients after MI. Methods: This randomized, double-blind, placebo-controlled study included 33 patients referred to Ayatollah Mousavi Hospital in Zanjan between 5 of September to 25 of December, 2024. Eligible patients with type 2 diabetes and MI who underwent primary percutaneous coronary intervention (PCI) were randomly assigned (17:16) to receive either 10 mg of EMPA daily or placebo for 12 weeks. Target genes expression levels were quantified by real time PCR, and data were analyzed by SPSS version 26. Results: Thirty-three patients were included in this study (mean age: 61.27±9.07, 66% male), mean diabetes duration was longer in intervention group (7.82±5.13) compared to placebo group (3.75±2.74), hypertension was the most common comorbidity (57%). CTF-1 expression in the intervention group was 0.3±0.28 and in placebo group was 5.66±6.52. GDF-15 expression in the intervention group was 0.198±0.22 and in placebo group was 1.66±1.04. EMPA significantly reduced expression of CTF-1 (13-fold) (P=0.003) and GDF-15 (7-fold) (P ˂ 0.0001). The CTF-1 and GDF-15 expression reduction were not associated with any other clinical variables. Significant reduction observed in LDL (P=0.045) and triglycerides (P=0.013) after intervention. Conclusion: EMPA significantly reduced the expression of CTF-1 and GDF-15 in type 2 diabetic, post MI patients, which are associated with atherosclerosis, and suggest that potential anti-atherosclerotic effect of EMPA mediated through modulation of GDF-15 and CTF-1 gene expression.
- 30 June 2026
- Published by Maad Rayan Publishing Company in Journal of Cardiovascular and Thoracic Research
- Vol. 18 (2) , 116-122
Open AccessImpact of Empagliflozin on mRNA Levels of Cardiotrophin-1 and GDF-15 in Patients with Type 2 Diabetes and ST-Segment Elevation Myocardial Infarction Undergoing PCI: A Double-Blind Pilot Trial
Introduction: Given the proven cardiovascular benefits of Empagliflozin (EM), we aimed to investigate the effect of Empagliflozin on Cardiotrophin-1 (CTF-1) and growth differentiation factor-15 (GDF-15) expressions in circulating monocytes in type 2 diabetic patients after MI. Methods: This randomized, double-blind, placebo-controlled study included 33 patients referred to Ayatollah Mousavi Hospital in Zanjan between 5 of September to 25 of December, 2024. Eligible patients with type 2 diabetes and MI who underwent primary percutaneous coronary intervention (PCI) were randomly assigned (17:16) to receive either 10 mg of EMPA daily or placebo for 12 weeks. Target genes expression levels were quantified by real time PCR, and data were analyzed by SPSS version 26. Results: Thirty-three patients were included in this study (mean age: 61.27±9.07, 66% male), mean diabetes duration was longer in intervention group (7.82±5.13) compared to placebo group (3.75±2.74), hypertension was the most common comorbidity (57%). CTF-1 expression in the intervention group was 0.3±0.28 and in placebo group was 5.66±6.52. GDF-15 expression in the intervention group was 0.198±0.22 and in placebo group was 1.66±1.04. EMPA significantly reduced expression of CTF-1 (13-fold) (P=0.003) and GDF-15 (7-fold) (P ˂ 0.0001). The CTF-1 and GDF-15 expression reduction were not associated with any other clinical variables. Significant reduction observed in LDL (P=0.045) and triglycerides (P=0.013) after intervention. Conclusion: EMPA significantly reduced the expression of CTF-1 and GDF-15 in type 2 diabetic, post MI patients, which are associated with atherosclerosis, and suggest that potential anti-atherosclerotic effect of EMPA mediated through modulation of GDF-15 and CTF-1 gene expression.
- Open Access
- 1 January 2023
- Published by Farname, Inc. in Journal of Advances in Medical and Biomedical Research
- Vol. 31 (144) , 32-39
Comparison of the Success Rate of Treatment with Primary Percutaneous Coronary Intervention PCI versus Thrombolytic Treatment in Patients with ST-Elevation Myocardial Infarction in Local Hospitals in Iran
Background and Objective: Acute myocardial infarction (MI) is caused due to coronary artery occlusion and divided into two forms of ST-elevation (STEMI) and non-ST-elevation (NSTEMI) myocardial infarction. This study aimed to determine the success rate of treatment with primary PCI (percutaneous coronary intervention) versus thrombolysis in the establishment of perfusion and ...
- 1 January 2023
- Published by Farname, Inc. in Journal of Advances in Medical and Biomedical Research
- Vol. 31 (144) , 32-39
Open AccessComparison of the Success Rate of Treatment with Primary Percutaneous Coronary Intervention PCI versus Thrombolytic Treatment in Patients with ST-Elevation Myocardial Infarction in Local Hospitals in Iran
Background and Objective: Acute myocardial infarction (MI) is caused due to coronary artery occlusion and divided into two forms of ST-elevation (STEMI) and non-ST-elevation (NSTEMI) myocardial infarction. This study aimed to determine the success rate of treatment with primary PCI (percutaneous coronary intervention) versus thrombolysis in the establishment of perfusion and ...